A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease
Paul Shotbolt1, Michael Samuel2,3, Chris Fox3,4, Anthony S David11Section of Cognitive Neuropsychiatry, Institute of Psychiatry, King’s College, London, UK; 2Department of Neurology, King’s College hospital, London, UK; 3East Kent hospitals NHS Trust, William Harvey Hospi...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2009
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/6e587c3603b044e4b2a262c004905109 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:6e587c3603b044e4b2a262c004905109 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:6e587c3603b044e4b2a262c0049051092021-12-02T03:44:12ZA randomized controlled trial of quetiapine for psychosis in Parkinson’s disease1176-63281178-2021https://doaj.org/article/6e587c3603b044e4b2a262c0049051092009-05-01T00:00:00Zhttp://www.dovepress.com/a-randomized-controlled-trial-of-quetiapine-for-psychosis-in-parkinson-a3162https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Paul Shotbolt1, Michael Samuel2,3, Chris Fox3,4, Anthony S David11Section of Cognitive Neuropsychiatry, Institute of Psychiatry, King’s College, London, UK; 2Department of Neurology, King’s College hospital, London, UK; 3East Kent hospitals NHS Trust, William Harvey Hospital, Ashford, Kent, UK; 4Kent and Medway NHS and Social Care and Partnership Trust, Kent, UKIntroduction: Psychosis (delusions and/or hallucinations) is a well-recognized complication of treatment of Parkinson’s disease (PD). Quetiapine is a currently favored treatment, but data on its efficacy are equivocal. This trial aimed to provide further evidence on the efficacy of quetiapine in PD psychosis.Methods: We conducted a 12 week double blind randomized placebo-controlled trial. Time to dropout due to lack of improvement of psychosis was the primary outcome measure. Other important secondary outcomes were evaluated using standard rating scales for PD and psychiatric symptoms.Results: Twenty-four eligible subjects gave consent. The primary outcome, time to dropout, was examined using survival analysis. It was shown that patients in the quetiapine group dropped out earlier than those in the placebo group, but this difference was not significant (p = 0.68). No significant changes were found for any of the secondary outcome measures in either group. Conclusions: In this study, quetiapine at doses of up to 150 mg/day failed to significantly improve psychosis compared to placebo, however the small sample size does not allow any conclusive interpretation of the results. Quetiapine did not appear to worsen PD motor functioning, but its use was limited by a faster drop out compared with placebo. Significant impediments were difficulty with recruitment and natural fluctuation in symptoms during the trial. Keywords: Parkinson’s disease, psychosis, antipsychotics, quetiapine Paul ShotboltMichael SamuelChris FoxAnthony S DavidDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2009, Iss default, Pp 327-332 (2009) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Paul Shotbolt Michael Samuel Chris Fox Anthony S David A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease |
| description |
Paul Shotbolt1, Michael Samuel2,3, Chris Fox3,4, Anthony S David11Section of Cognitive Neuropsychiatry, Institute of Psychiatry, King’s College, London, UK; 2Department of Neurology, King’s College hospital, London, UK; 3East Kent hospitals NHS Trust, William Harvey Hospital, Ashford, Kent, UK; 4Kent and Medway NHS and Social Care and Partnership Trust, Kent, UKIntroduction: Psychosis (delusions and/or hallucinations) is a well-recognized complication of treatment of Parkinson’s disease (PD). Quetiapine is a currently favored treatment, but data on its efficacy are equivocal. This trial aimed to provide further evidence on the efficacy of quetiapine in PD psychosis.Methods: We conducted a 12 week double blind randomized placebo-controlled trial. Time to dropout due to lack of improvement of psychosis was the primary outcome measure. Other important secondary outcomes were evaluated using standard rating scales for PD and psychiatric symptoms.Results: Twenty-four eligible subjects gave consent. The primary outcome, time to dropout, was examined using survival analysis. It was shown that patients in the quetiapine group dropped out earlier than those in the placebo group, but this difference was not significant (p = 0.68). No significant changes were found for any of the secondary outcome measures in either group. Conclusions: In this study, quetiapine at doses of up to 150 mg/day failed to significantly improve psychosis compared to placebo, however the small sample size does not allow any conclusive interpretation of the results. Quetiapine did not appear to worsen PD motor functioning, but its use was limited by a faster drop out compared with placebo. Significant impediments were difficulty with recruitment and natural fluctuation in symptoms during the trial. Keywords: Parkinson’s disease, psychosis, antipsychotics, quetiapine |
| format |
article |
| author |
Paul Shotbolt Michael Samuel Chris Fox Anthony S David |
| author_facet |
Paul Shotbolt Michael Samuel Chris Fox Anthony S David |
| author_sort |
Paul Shotbolt |
| title |
A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease |
| title_short |
A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease |
| title_full |
A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease |
| title_fullStr |
A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease |
| title_full_unstemmed |
A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease |
| title_sort |
randomized controlled trial of quetiapine for psychosis in parkinson’s disease |
| publisher |
Dove Medical Press |
| publishDate |
2009 |
| url |
https://doaj.org/article/6e587c3603b044e4b2a262c004905109 |
| work_keys_str_mv |
AT paulshotbolt arandomizedcontrolledtrialofquetiapineforpsychosisinparkinsonamprsquosdisease AT michaelsamuel arandomizedcontrolledtrialofquetiapineforpsychosisinparkinsonamprsquosdisease AT chrisfox arandomizedcontrolledtrialofquetiapineforpsychosisinparkinsonamprsquosdisease AT anthonysdavid arandomizedcontrolledtrialofquetiapineforpsychosisinparkinsonamprsquosdisease AT paulshotbolt randomizedcontrolledtrialofquetiapineforpsychosisinparkinsonamprsquosdisease AT michaelsamuel randomizedcontrolledtrialofquetiapineforpsychosisinparkinsonamprsquosdisease AT chrisfox randomizedcontrolledtrialofquetiapineforpsychosisinparkinsonamprsquosdisease AT anthonysdavid randomizedcontrolledtrialofquetiapineforpsychosisinparkinsonamprsquosdisease |
| _version_ |
1718401633395671040 |